{"nctId":"NCT03717506","briefTitle":"Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris","startDateStruct":{"date":"2018-10-10","type":"ACTUAL"},"conditions":["Acne Vulgaris"],"count":1236,"armGroups":[{"label":"Test product","type":"EXPERIMENTAL","interventionNames":["Drug: GDC 268 Lotion"]},{"label":"Reference Product","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Clindamycin Phosphate Lotion 1%"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: GDC Vehicle Lotion"]}],"interventions":[{"name":"GDC 268 Lotion","otherNames":[]},{"name":"Clindamycin Phosphate Lotion 1%","otherNames":[]},{"name":"GDC Vehicle Lotion","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or non-pregnant, non-lactating female, ≥12 and ≤40 years of age with a clinical diagnosis of acne vulgaris.\n* Must have ≥ 25 but ≤ 100 non-inflammatory lesions (open and closed comedones) AND ≥ 20 but ≤ 70 inflammatory lesions (papules and pustules) AND ≤ 2 nodulocystic lesions (nodules and cysts) on the face (e.g., forehead, nose, cheeks, chin, upper lip) at Baseline.\n* Must be willing and able to refrain from use of all other topical products in the treatment area, all acne medications other than test article, and all antibiotics (other than test article) during the 12-week treatment period.\n* Women must be surgically sterile, or use an effective method of birth control with a negative urine pregnancy test (UPT) at the Baseline Visit (Day 1).\n* In good general health and free of any other clinically significant disease state or physical condition.\n* Subject has provided written informed consent / assent.\n\nExclusion Criteria:\n\n* Subject is pregnant, breastfeeding, or is planning to become pregnant or breastfeed during the study.\n* Subject has more than 2 facial nodular lesions; any nodules present will be documented but not included in the inflammatory lesion count for analysis.\n* Subject has excessive facial hair (e.g., beards, sideburns, moustaches), facial tattoos, or other facial attributes that would interfere with diagnosis or assessment of acne vulgaris in the opinion of the investigator.\n* Subject is planning surgery during the study.\n* Subject has a history of hypersensitivity or allergy to clindamycin or lincomycin and/or any of the ingredients in the test articles.\n\nOther Eligibility Criteria not listed above will be reviewed for each prospective subject by the study staff.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"40 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Percent Change in the Number of Inflamed Lesions","description":"Percent Change from Baseline to Week 12 in inflammatory lesion counts (Papules/Pustules).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.4","spread":"36.10"},{"groupId":"OG001","value":"-40.0","spread":"36.83"},{"groupId":"OG002","value":"-35.1","spread":"35.54"}]}]}]},{"type":"PRIMARY","title":"Mean Percent Change in the Non-inflammatory Lesion Counts","description":"Percent Change (i.e., reduction) from Baseline to Week 12 in non-inflammatory (open and closed comedones) lesion counts.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-52.7","spread":"33.98"},{"groupId":"OG001","value":"-54.3","spread":"34.44"},{"groupId":"OG002","value":"-43.0","spread":"39.13"}]}]}]},{"type":"SECONDARY","title":"The Percentage of Subjects With a Clinical Response (IGA) of \"Success\" at Week 12","description":"Investigator's Global Assessment, IGA. Overall severity of acne was assessed using a five-point scale from 0=Clear to 4=Severe. Subjects must have had an IGA score of 2 (mild), 3 (moderate), or 4 (severe) at Baseline. Success is defined as an IGA score at week 12 that is at least 2 grades less than the baseline assessment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence of Adverse Events","description":"Adverse Events (AEs) will be assessed by the investigator and the incidence (severity and causality) of any local and systemic AEs will be reported by number and percentage.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":496},"commonTop":[]}}}